Ian M. Thompson

63.4k citations

897 papers · 37.6k indexed · 19 hit papers · h-index 89

Pulmonary and Respiratory Medicine top 0.01%
Molecular Biology top 0.5%
Oncology top 0.2%
Surgery top 0.2%
Cancer Research top 0.1%

Co-authors: Catherine M. Tangen Phyllis J. Goodman M. Scott Lucia Charles A. Coltman Scott M. Lippman Howard L. Parnes Javier Hernández Donna P. Ankerst
Topics: Prostate Cancer Treatment and Research (378 papers)Prostate Cancer Diagnosis and Treatment (337 papers)Bladder and Urothelial Cancer Treatments (107 papers)
Cited by: Pulmonary and Respiratory Medicine Urology Cancer Research
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: United States Canada United Kingdom

In The Last Decade

Ian M. Thompson

872 papers receiving 36.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Influence of Finasteride on the Development of Prostate Cancer

2003 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. profile →
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

2004 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. profile →
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update

2007 864 citations Ian M. Thompson, Edith Canby‐Hagino et al. profile →
Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

2009 826 citations Ian M. Thompson, Catherine M. Tangen et al. profile →
American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010

2010 736 citations Ian M. Thompson et al. profile →
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

1998 685 citations E. David Crawford, Ian M. Thompson et al. profile →
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer

2006 664 citations Ian M. Thompson, Catherine M. Tangen et al. profile →
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

2006 658 citations Ian M. Thompson, Phyllis J. Goodman et al. profile →
Erectile Dysfunction and Subsequent Cardiovascular Disease

2005 654 citations Ian M. Thompson profile →
Investigation, treatment and monitoring of late-onset hypogonadism in males

2008 646 citations Ian M. Thompson et al. profile →
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes

2007 631 citations Edith Canby‐Hagino, Jeffrey D. Forman et al. profile →
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy

2016 489 citations John T. Wei, Ian M. Thompson et al. profile →
Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower

2005 485 citations Ian M. Thompson profile →
Addressing overdiagnosis and overtreatment in cancer: a prescription for change

2014 351 citations Ian M. Thompson, Peter S. Nelson et al. profile →
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

2013 350 citations Ian M. Thompson et al. Journal of Clinical Oncology profile →
Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline

2013 289 citations Ian M. Thompson, Eric A. Klein et al. profile →
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy

2018 209 citations Ian M. Thompson, Peter R. Carroll et al. European Urology profile →
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening

2023 172 citations John T. Wei, Ian M. Thompson et al. profile →
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

2021 170 citations Catherine M. Tangen, Ian M. Thompson et al. profile →

Peers

Countries citing papers authored by Ian M. Thompson

Since Specialization

Citations

This map shows the geographic impact of Ian M. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian M. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian M. Thompson more than expected).

Fields of papers citing papers by Ian M. Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian M. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian M. Thompson. The network helps show where Ian M. Thompson may publish in the future.

Co-authorship network of co-authors of Ian M. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Ian M. Thompson. A scholar is included among the top collaborators of Ian M. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian M. Thompson. Ian M. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597] 2024 ·Urologic Oncology Seminars and Original Investigations ·Hyung L. Kim,Catherine M. Tangen,Ulka N. Vaishampayan,Abhishek Tripathi,(unknown),Brian Shuch,Pedro C. Barata,Alan Tan,(unknown),Primo N. Lara,Alejandro Sánchez,Seth P. Lerner,Ian M. Thompson	2
2	Objects of coalescence: Using LA-ICP-MS to study ceramics recovered from an eighteenth-century Choctaw village 2024 ·Journal of Archaeological Science Reports ·(unknown),(unknown),Ian M. Thompson,Laure Dussubieux	0
3	An approximate unique extension property for completely positive maps 2023 ·Journal of Functional Analysis ·Ian M. Thompson	2
4	Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605 2023 ·European Urology ·Peter C. Black,Catherine M. Tangen,Parminder Singh,David J. McConkey,M. Scott Lucia,William T. Lowrance,Vadim S. Koshkin,Kelly Stratton,Trinity J. Bivalacqua,Wassim Kassouf,Sima P. Porten,Rick Bangs,Melissa Plets,Ian M. Thompson,Seth P. Lerner	48
5	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) 2021 ·Clinical Cancer Research ·Thomas W. Flaig,Catherine M. Tangen,Siamak Daneshmand,Ajjai Alva,Seth P. Lerner,M. Scott Lucia,David J. McConkey,Dan Theodorescu,Amir Goldkorn,Matthew I. Milowsky,Rick Bangs,Gary R. MacVicar,Bruno R. Bastos,Jared S. Fowles,Daniel L. Gustafson,Melissa Plets,Ian M. Thompson	58
6	Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression 2021 ·Cancer Prevention Research ·Phillip M. Kemp Bohan,Robert C. Chick,(unknown),Timothy J. Vreeland,(unknown),(unknown),(unknown),Diane F. Hale,Guy T. Clifton,Vance Y. Sohn,Ian M. Thompson,George E. Peoples,Michael A. Liss	9
7	Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial 2020 ·Cancer Prevention Research ·Lauren M. Hurwitz,İbrahim Kulaç,Berrak Gümüşkaya,Javier Baena-Del Valle,(unknown),Fan Pan,Jun O. Liu,Michael Marrone,Kathryn B. Arnold,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Ian M. Thompson,Charles G. Drake,William B. Isaacs,William G. Nelson,Angelo M. De Marzo,Elizabeth A. Platz	7
8	Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial 2020 ·Cancer Prevention Research ·Kathleen C. Torkko,Cathee Till,Catherine M. Tangen,Phyllis J. Goodman,Xiaoling Song,Jeannette M. Schenk,M. Scott Lucia,Ulrike Peters,Adrie van Bokhoven,Ian M. Thompson,Marian L. Neuhouser	4
9	Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride 2018 ·Cancer Prevention Research ·James Y. Dai,Michael LeBlanc,Phyllis J. Goodman,M. Scott Lucia,Ian M. Thompson,Catherine M. Tangen	2
10	Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes 2016 ·Cancer Prevention Research ·Chen-Pin Wang,Donna M. Lehman,(unknown),John G. Kuhn,Devalingam Mahalingam,Steven Weitman,Carlos Lorenzo,John R. Downs,Elizabeth A. Stuart,Javier Hernández,Ian M. Thompson,Amelie G. Ramírez	20
11	Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial 2015 ·Cancer Prevention Research ·Sarah H. Nash,Jeannette M. Schenk,Alan R. Kristal,(unknown),M. Scott Lucia,Howard L. Parnes,Ian M. Thompson,Scott M. Lippman,Xiaoling Song,Bora Gürel,Angelo De Marzo,Elizabeth A. Platz	8
12	Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 2014 ·Cancer Prevention Research ·Demetrius Albanes,Cathee Till,Eric A. Klein,Phyllis J. Goodman,Alison M. Mondul,Stephanie J. Weinstein,Philip R. Taylor,Howard L. Parnes,J. Michael Gaziano,Xiaoling Song,Neil Fleshner,Powel H. Brown,Frank L. Meyskens,Ian M. Thompson	49
13	Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer 2013 ·Clinical Cancer Research ·Ya‐Ting Hsu,Fei Gu,Yi-Wen Huang,Joseph K. Liu,Jianhua Ruan,Rui Huang,Chiou-Miin Wang,Chun‐Liang Chen,Rohit R. Jadhav,Hung‐Cheng Lai,David G. Mutch,Paul J. Goodfellow,Ian M. Thompson,Nameer B. Kirma,(unknown)	36
14	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study 2013 ·Clinical Cancer Research ·Daniel W. Lin,Lisa F. Newcomb,Elissa C. Brown,James D. Brooks,Peter R. Carroll,Ziding Feng,Martin Gleave,Raymond S. Lance,Martin G. Sanda,Ian M. Thompson,John T. Wei,Peter S. Nelson,(unknown)	111
15	Limited PSA Testing in Indigent Men in South Texas: An Appropriate Care or Missing a Prevention Opportunity? 2012 ·Cancer Epidemiology Biomarkers & Prevention ·Yuanyuan Liang,Fei Du,Ian M. Thompson,Barbara J. Turner	2
16	Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917 2011 ·Cancer Prevention Research ·James R. Marshall,Catherine M. Tangen,Wael Sakr,David P. Wood,Donna L. Berry,Eric A. Klein,Scott M. Lippman,Howard L. Parnes,David S. Alberts,David F. Jarrard,W. Robert Lee,J. Michael Gaziano,E. David Crawford,Benjamin Ely,Michael Ray,Warren Davis,Lori M. Minasian,Ian M. Thompson	83
17	Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial 2009 ·Cancer Epidemiology Biomarkers & Prevention ·Elizabeth A. Platz,Cathee Till,Phyllis J. Goodman,Howard L. Parnes,William D. Figg,Demetrius Albanes,Marian L. Neuhouser,Eric A. Klein,Ian M. Thompson,Alan R. Kristal	133
18	Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention 2008 ·Cancer Prevention Research ·M. Scott Lucia,Amy K. Darke,Phyllis J. Goodman,Francisco G. La Rosa,Howard L. Parnes,Leslie G. Ford,Charles A. Coltman,Ian M. Thompson	72
19	Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach 2008 ·Cancer Prevention Research ·Mary W. Redman,Catherine M. Tangen,Phyllis J. Goodman,M. Scott Lucia,Charles A. Coltman,Ian M. Thompson	140
20	Predominant Treatment Failure in Postprostatectomy Patients Is Local: Analysis of Patterns of Treatment Failure in SWOG 8794 2007 ·Journal of Clinical Oncology ·Gregory P. Swanson,Michael A. Hussey,Catherine M. Tangen,Joseph L. Chin,Edward M. Messing,Edith Canby‐Hagino,Jeffrey D. Forman,Ian M. Thompson,E. David Crawford	198

About Ian M. Thompson

Ian M. Thompson is a scholar working on Urology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 897 papers that have together received 37.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (378 papers), Prostate Cancer Diagnosis and Treatment (337 papers) and Bladder and Urothelial Cancer Treatments (107 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (20.6k citations), Urology (3.6k citations) and Cancer Research (5.3k citations). Ian M. Thompson has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Catherine M. Tangen, Phyllis J. Goodman, M. Scott Lucia, Charles A. Coltman, Scott M. Lippman, Howard L. Parnes, Javier Hernández, Donna P. Ankerst, Leslie G. Ford and Edith Canby‐Hagino. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact